OpenAI has introduced a new artificial intelligence model called GPT-Rosalind to help scientists accelerate life science research, including studies in biology and drug discovery.
According to an OpenAI blog post published on Thursday (April 16), the AI model is named after Rosalind Franklin, whose groundbreaking research helped reveal the structure of DNA and laid the foundation for modern molecular biology.
Scientific research depends heavily on data, and GPT-Rosalind is designed to assist researchers in sorting complex information more efficiently. It also aims to reduce the time required to develop, approve, and bring new medicines to market.
OpenAI stated that developing and gaining approval for a new drug in the United States typically takes between 10 to 15 years.
As reported by CNET on Friday (April 17), GPT-Rosalind is built to improve target selection in research and generate stronger hypotheses, leading to higher-quality experiments.
The model has already been tested in areas such as organic chemistry, proteins, and genetics. Researchers can use it to discover relevant scientific literature and design more effective experiments.
OpenAI is not alone in this field. Google DeepMind has also developed AI models for scientific research, including AlphaFold, which contributed to its creators receiving part of the 2024 Nobel Prize in Chemistry.
“For me, the best use of AI is to improve human health and accelerate scientific discovery,” said Google DeepMind CEO Demis Hassabis.
Earlier this year, Anthropic also launched Claude for Life Sciences with a similar purpose.
However, some scientists have expressed concerns about the rapid integration of AI into science, warning about potential vulnerabilities, misuse, and data representation issues in AI-powered research.
OpenAI stated that GPT-Rosalind includes strong safety measures to prevent misuse, such as the creation of biological weapons. The company has also partnered with biotechnology, pharmaceutical, and life science organizations to support research and innovation.
GPT-Rosalind is now available as a research preview on ChatGPT, Codex, and API access for eligible customers through OpenAI’s trusted access program.
OpenAI is collaborating with companies such as Amgen, Moderna, Allen Institute, and Thermo Fisher Scientific to apply GPT-Rosalind across research workflows and accelerate scientific discoveries.
Sean Bruich, Senior Vice President of Artificial Intelligence and Data at Amgen, emphasized the importance of precision in scientific work.
“Our unique collaboration with OpenAI allows us to apply their most advanced capabilities and tools in new and innovative ways that could potentially speed up how we deliver medicines to patients,” he said.
0 Comments